Arthritis & Rheumatology
Arthritis Care & Research
ACR Open Rheumatology
SoMe Editor: Karen Costenbader, MD, MPH
#Medsky #geriatrics
#Medsky #geriatrics
Arthritis & Rheumatology
doi.org/10.1002/art....
↓
Arthritis & Rheumatology
doi.org/10.1002/art....
↓
Case report in ACR Open Rheumatology
https://doi.org/10.1002/acr2.70136
#Medsky
Case report in ACR Open Rheumatology
https://doi.org/10.1002/acr2.70136
#Medsky
Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky
Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky
Multiple regression equations to predict peak V̇O₂
Multiple regression equations to predict peak V̇O₂
A&R
doi.org/10.1002/art....
A&R
doi.org/10.1002/art....
doi.org/10.1002/acr....
↓
doi.org/10.1002/acr....
↓
Clinical images in Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky
Clinical images in Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky
"[This trial] represents an extremely important first attempt and has already taught us much about the possibility of 'preventing' SLE and how we might improve the design of future trials, because there will and should be more."
#Medsky
"[This trial] represents an extremely important first attempt and has already taught us much about the possibility of 'preventing' SLE and how we might improve the design of future trials, because there will and should be more."
#Medsky
Anti-collagen II antibodies neither sensitive nor specific for relapsing polychondritis
doi.org/10.1002/acr....
Phase 2b study: sarilumab in severe polyarticular JIA
doi.org/10.1002/acr....
↓
Anti-collagen II antibodies neither sensitive nor specific for relapsing polychondritis
doi.org/10.1002/acr....
Phase 2b study: sarilumab in severe polyarticular JIA
doi.org/10.1002/acr....
↓
Colchicine initiation after gout dx assoc. with modestly lower risk of total joint arthroplasty doi.org/10.1002/art....
Vorinostat suppresses IFN-I production in an SLE model
doi.org/10.1002/art....
↓
Colchicine initiation after gout dx assoc. with modestly lower risk of total joint arthroplasty doi.org/10.1002/art....
Vorinostat suppresses IFN-I production in an SLE model
doi.org/10.1002/art....
↓
Arthritis & Rheumatology
doi.org/10.1002/art....
Arthritis & Rheumatology
doi.org/10.1002/art....
📄 🔓 Read the open access review: doi.org/10.1002/acr....
#Medsky
📄 🔓 Read the open access review: doi.org/10.1002/acr....
#Medsky
Arthritis Care & Research
doi.org/10.1002/acr....
#Medsky
Arthritis Care & Research
doi.org/10.1002/acr....
#Medsky
Arthritis Care & Research
doi.org/10.1002/acr....
#Medsky
Arthritis Care & Research
doi.org/10.1002/acr....
#Medsky
• Selected optimal doses: 3.0 mg/kg q2w for patients weighing ≥30 kg, 4.0 mg/kg q2w for ≥10–<30 kg, which yielded exposures similar to approved dose of 200 mg q2w in adults with RA
↓ continues
• Selected optimal doses: 3.0 mg/kg q2w for patients weighing ≥30 kg, 4.0 mg/kg q2w for ≥10–<30 kg, which yielded exposures similar to approved dose of 200 mg q2w in adults with RA
↓ continues
•lower copy numbers (CNs) of C4 were associated with increased risk of different clinical and serologic subtypes of SSc
↓ continues
•lower copy numbers (CNs) of C4 were associated with increased risk of different clinical and serologic subtypes of SSc
↓ continues
Arthritis & Rheumatology
doi.org/10.1002/art....
Arthritis & Rheumatology
doi.org/10.1002/art....
Arthritis & Rheumatology
doi.org/10.1002/art....
Figure: Immunologic cell subset and cytokines linked to OA-pain with MRI bone marrow lesions and knee effusion
Arthritis & Rheumatology
doi.org/10.1002/art....
Figure: Immunologic cell subset and cytokines linked to OA-pain with MRI bone marrow lesions and knee effusion
Arthritis Care & Research
doi.org/10.1002/acr....
#Medsky
Arthritis Care & Research
doi.org/10.1002/acr....
#Medsky
Arthritis & Rheumatology
doi.org/10.1002/art....
Arthritis & Rheumatology
doi.org/10.1002/art....
UK population-based cohort study (IQVIA Medical Research Database)
Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky
UK population-based cohort study (IQVIA Medical Research Database)
Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky
•25% (4/16) developed dry digital gangrene
•median time to onset 44.5 days (range 8–90) post-op
•all SSc pts w/ gangrene also had diabetes
•median survival time with digital gangrene was sign. shorter
•25% (4/16) developed dry digital gangrene
•median time to onset 44.5 days (range 8–90) post-op
•all SSc pts w/ gangrene also had diabetes
•median survival time with digital gangrene was sign. shorter
Clinical images in Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky #Cardiosky
Clinical images in Arthritis & Rheumatology
doi.org/10.1002/art....
#Medsky #Cardiosky
Clinical images in A&R
doi.org/10.1002/art....
#Medsky
Clinical images in A&R
doi.org/10.1002/art....
#Medsky